Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 127 |
| Active Pipeline (Recruiting Now) | 78 (40) |
| Completed vs Stopped Early | 12 / 1 (0.8%) |
| Median Closed Actual Enrollment | 79 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| West China Hospital,Sichuan University | Chengdu, Sichuan | 34 |
| West China Hospital of Sichuan University | Chengdu, Sichuan | 19 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07855965 | Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Rese | Phase II | RECRUITING |
| NCT07776522 | Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the West China Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.